VectivBio AG is a clinical-stage biotechnology company focused on rare conditions with a well-defined biology that can be targeted with transformational therapeutics.
VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with se...
VectivBio AG is a clinical-stage biotechnology company focused on rare conditions with a well-defined biology that can be targeted with transformational therapeutics.
VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and business development for innovative products.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.